Palisade Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Palisade Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-21,614	Closed	-$1.53M	–	520
2016 Q3	$1.53M	Sell	21,614 -3,151	-13%	-$201K	0.05%	368
2016 Q2	$1.21M	Buy	24,765 +6,589	+36%	+$426K	0.04%	395
2016 Q1	$1.15M	Buy	18,176 +12,889	+244%	+$843K	0.04%	409
2015 Q4	$593K	Sell	5,287 -6,274	-54%	-$627K	0.02%	461
2015 Q3	$1.11M	Sell	11,561 -42,151	-78%	-$4.83M	0.03%	400
2015 Q2	$5.5M	Sell	53,712 -1,269	-2%	-$98.5K	0.14%	255
2015 Q1	$3.41M	Buy	+54,981	New	+$3.05M	0.09%	307

Other funds holding RARE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Palisade Capital Management's RARE Position: Q4 2016 in Review

Palisade Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2016, closing a stake of 21,614 shares — an estimated $1.53M sold.

Palisade Capital Management first reported a position in RARE in Q1 2015 and held it in 7 quarters. The position peaked at $5.5M in Q2 2015. 174 funds tracked by Wall St. Rank hold RARE as of Q4 2016.

Palisade Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2016 after selling out during the quarter.
Palisade Capital Management sold 21,614 Ultragenyx Pharmaceutical shares in Q4 2016, an estimated $1.53M.
Palisade Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and held it in 7 quarters.
Palisade Capital Management's Ultragenyx Pharmaceutical position peaked at $5.5M in Q2 2015.
174 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2016.

Based on Palisade Capital Management's 13F filing for Q4 2016, filed 31 Jan 2017.